文献速递消化系统肿瘤

接受标准治疗的结直肠癌患者DNA突变谱分析揭示结局差异与突变的种族分布差异

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
PubMed 文献 · J Clin Oncol · 2023-11-22

CALGB(Alliance)/SWOG 80405是一项随机III期试验,针对转移性结直肠癌一线接受贝伐珠单抗或西妥昔单抗联合化疗的患者。对548例患者原发肿瘤DNA行FoundationOne测序,校正微卫星不稳定状态、BRAF V600E、所有RAS突变、治疗臂、性别和年龄后,分析突变基因与总生存的关系,发现LRP1B突变与总生存改善相关,RNF43突变与治疗臂存在交互作用,KRAS、APC、BRAF V600E突变频率在Black与White患者间存在差异。

要点

  • LRP1B突变(10.7%患者)与总生存改善相关,风险比0.57(95%CI 0.40-0.80)。
  • RNF43突变(5.6%患者)与治疗臂存在交互作用:西妥昔单抗臂中突变型中位OS 11.5个月 vs 野生型30.1个月;贝伐珠单抗臂中突变型25.0个月 vs 野生型31.3个月。
  • KRAS和APC突变在Black患者中更常见(53%和85%),White患者分别为27%和65%;BRAF V600E在Black患者中较少见(5% vs 14%)。

核心结论

  • 这些结果可为预测患者结局、改善治疗决策和少数族裔患者参与试验提供新工具。
  • 本研究发现的分子改变可能指导生物标志物驱动的研究。

研究设计与样本

  • CALGB(Alliance)/SWOG 80405是一项随机III期试验,入组转移性结直肠癌一线接受贝伐珠单抗或西妥昔单抗联合化疗的患者。
  • 对548例患者原发肿瘤DNA使用FoundationOne进行测序。
  • 分析突变基因和突变对总生存的影响,校正微卫星不稳定状态、BRAF V600E、所有RAS突变、治疗臂、性别和年龄。

主要发现

  • 突变基因数中位数(下-上四分位数)为5(3-7);微卫星稳定肿瘤为5(3-6),微卫星高度不稳定肿瘤为12.5(4.5-32)。
  • KRAS和APC突变在Black患者中更常见(53%和85%),White患者分别为27%和65%;BRAF V600E在Black患者中较少见(5% vs 14%)。
  • BRAF非V600E突变患者(2.2%)中位OS为31.9个月(95%CI 15.1至不适用[NA]),与BRAF野生型患者(31.2个月[95%CI 29.0-33.9])相似。
  • LRP1B突变(10.7%患者)与总生存改善相关,风险比0.57(95%CI 0.40-0.80)。
  • RNF43突变(5.6%患者)与治疗臂存在交互作用:西妥昔单抗臂中突变型中位OS 11.5个月(95%CI 10.8至NA) vs 野生型30.1个月(95%CI 24.9-35.3);贝伐珠单抗臂中突变型25.0个月(95%CI 14.2至NA) vs 野生型31.3个月(95%CI 29.0-34.3)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab with chemotherapy. We aimed to discover novel mutated genes associated with prognosis and differential response to therapy with the biologics. METHODS: Primary tumor DNA from 548 patients was sequenced using FoundationOne. The effect of mutated genes and mutations on overall survival (OS) was tested adjusting for microsatellite instability status, BRAF V600E, all RAS mutations, arm, sex, and age. RESULTS: The median number (lower-upper quartile) of mutated genes was 5 (3-7), 5 (3-6) in microsatellite stable and 12.5 (4.5-32) in microsatellite instability-high tumors. Mutated KRAS and APC were more frequent in Black (53% and 85%) than White (27% and 65%, respectively) patients while BRAF V600E was less frequent in Black (5%) than White (14%) patients. The median OS in patients with BRAF non-V600E (2.2% of patients) was 31.9 months (95% CI, 15.1 to not applicable [NA]) similar to that of BRAF wild-type (WT) patients (31.2 months [95% CI, 29.0 to 33.9]). Mutated LRP1B (10.7% of patients) was associated with improved OS compared with WT LRP1B (hazard ratio, 0.57 [95% CI, 0.40 to 0.80]). RNF43 (5.6% of patients) interacted with treatment arms as, in the cetuximab arm, patients with mutated RNF43 had a median OS of 11.5 (95% CI, 10.8 to NA) months compared with 30.1 (95% CI, 24.9 to 35.3) months in patients with WT RNF43, whereas in the bevacizumab arm, patients with mutated RNF43 had a median OS of 25.0 (95% CI, 14.2 to NA) months compared with 31.3 (95% CI, 29.0 to 34.3) months in patients with WT RNF43. CONCLUSION: These results can provide new tools to predict patient outcome and improve therapeutic decisions and trial participation in patient minorities. The molecular alterations identified in this study may direct biomarker-driven studies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Innocenti F, Mu W, Qu X, et al. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. J Clin Oncol. 2023. PMID: 37992266. doi:10.1200/JCO.23.00825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。